Krystina L. Hess

Krystina L. Hess

Auto-generated profile, based on publicly available information

Krystina L. Hess

U.S. Army Combat Capabilities Development Command Chemical Biological Center Aberdeen Proving Ground Maryland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2019 in Nano Today
Verified
Journal Article
Closed access
KHKrystina L. Hess
Krystina L. Hess
Igor MedintzIgor Medintz
Igor Medintz
CJChristopher Jewell
Christopher Jewell

27 August 2019 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
PDF file
KHKrystina L. Hess
Krystina L. Hess
CJChristopher Jewell
Christopher Jewell
Bacteriophages, or phages, are viruses that specifically infect bacteria and coopt the cellular machinery to create more phage proteins, eventually resulting in the release of new phage particles. Phages are heavily utilized in bioengineering for applications ranging from tissue engineering scaffolds to immune signal delivery. Of specific interest to vaccines and immunotherapies, phages have demonstrated an ability to activate both the innate and adaptive immune systems. The genome of these viral particles can be harnessed for DNA vaccination, or the surface proteins can be exploited for antigen display. More specifically, genes that encode an antigen of interest can be spliced into the phage genome, allowing antigenic proteins or peptides to be displayed by fusion to phage capsid proteins. Phages therefore present antigens to immune cells in a highly ordered and repetitive manner. This review discusses the use of phage with adjuvanting activity as antigen delivery vehicles for vaccination against infectious disease and cancer.

1 March 2016 in Acta Biomaterialia
Verified
Journal Article
Open access
JAJames I. Andorko
James I. Andorko
KHKrystina L. Hess
Krystina L. Hess
KPKevin G. Pineault
Kevin G. Pineault
CJChristopher Jewell
Christopher Jewell
Recent studies reveal many biomaterial vaccine carriers are able to activate immunostimulatory pathways, even in the absence of other immune signals. How the changing properties of polymers during biodegradation impact this intrinsic immunogenicity is not well studied, yet this information could contribute to rational design of degradable vaccine carriers that help direct immune response. We use degradable poly(beta-amino esters) (PBAEs) to explore intrinsic immunogenicity as a function of the degree of polymer degradation and polymer form (e.g., soluble, particles). PBAE particles condensed by electrostatic interaction to mimic a common vaccine approach strongly activate dendritic cells, drive antigen presentation, and enhance T cell proliferation in the presence of antigen. Polymer molecular weight strongly influences these effects, with maximum stimulation at short degradation times--corresponding to high molecular weight--and waning levels as degradation continues. In contrast, free polymer is immunologically inert. In mice, PBAE particles increase the numbers and activation state of cells in lymph nodes. Mechanistic studies reveal that this evolving immunogenicity occurs as the physicochemical properties and concentration of particles change during polymer degradation. This work confirms the immunological profile of degradable, synthetic polymers can evolve over time and creates an opportunity to leverage this feature in new vaccines. Degradable polymers are increasingly important in vaccination, but how the inherent immunogenicity of polymers changes during degradation is poorly understood. Using common rapidly-degradable vaccine carriers, we show that the activation of immune cells--even in the absence of other adjuvants--depends on polymer form (e.g., free, particulate) and the extent of degradation. These changing characteristics alter the physicochemical properties (e.g., charge, size, molecular weight) of polymer particles, driving changes in immunogenicity. Our results are important as many common biomaterials (e.g., PLGA) are now known to exhibit immune activity that alters how vaccines are processed. Thus, the results of this study could contribute to more rational design of biomaterial carriers that also actively direct the properties of responses generated by vaccines.

23 December 2014 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
JAJames I. Andorko
James I. Andorko
KHKrystina L. Hess
Krystina L. Hess
CJChristopher Jewell
Christopher Jewell
Nanoparticles, microparticles, and other biomaterials are advantageous in vaccination because these materials provide opportunities to modulate specific characteristics of immune responses. This idea...

3 April 2017 in Advanced Functional Materials
Verified
Journal Article
Open access
PDF file
KHKrystina L. Hess
Krystina L. Hess
EOEunkeu Oh
Eunkeu Oh
LTLisa H. Tostanoski
Lisa H. Tostanoski
JAJames I. Andorko
James I. Andorko
KSKimihiro Susumu
Kimihiro Susumu
CJChristopher Jewell
Christopher Jewell
Treatments for autoimmunity—diseases where the immune system mistakenly attacks self‐molecules—are not curative and leave patients immunocompromised. New studies aimed at more specific treatments reveal that development of inflammation or tolerance is influenced by the form in which self‐antigens are presented. Using a mouse model of multiple sclerosis (MS), it is shown for the first time that quantum dots (QDs) can be used to generate immunological tolerance by controlling the density of self‐antigen on QDs. These assemblies display dense arrangements of myelin self‐peptide associated with disease in MS, are uniform in size (<20 nm), and allow direct visualization in immune tissues. Peptide‐QDs rapidly concentrate in draining lymph nodes, colocalizing with macrophages expressing scavenger receptors involved in tolerance. Treatment with peptide‐QDs reduces disease incidence tenfold. Strikingly, the degree of tolerance—and the underlying expansion of regulatory T cells—correlates with the density of myelin molecules presented on QDs. A key discovery is that higher numbers of tolerogenic particles displaying lower levels of self‐peptide are more effective for inducing tolerance than fewer particles each displaying higher densities of peptide. QDs conjugated with self‐antigens can serve as a new platform to induce tolerance, while visualizing QD therapeutics in tolerogenic tissue domains.

1 February 2017 in Biomaterials
Verified
Journal Article
Open access
KHKrystina L. Hess
Krystina L. Hess
JAJames I. Andorko
James I. Andorko
LTLisa H. Tostanoski
Lisa H. Tostanoski
CJChristopher Jewell
Christopher Jewell
Autoimmune diseases occur when the immune system incorrectly recognizes self-molecules as foreign; in the case of multiple sclerosis (MS), myelin is attacked. Intriguingly, new studies reveal toll-like receptors (TLRs), pathways usually involved in generating immune responses against pathogens, play a significant role in driving autoimmune disease in both humans and animal models. We reasoned polyplexes formed from myelin self-antigen and regulatory TLR antagonists might limit TLR signaling during differentiation of myelin-specific T cells, inducing tolerance by biasing T cells away from inflammatory phenotypes. Complexes were formed by modifying myelin peptide with cationic amino acids to create peptides able to condense the anionic nucleic-acid based TLR antagonist. These immunological polyplexes eliminate synthetic polymers commonly used to condense polyplexes and do not rely on gene expression; however, the complexes mimic key features of traditional polyplexes such as tunable loading and co-delivery. Using these materials and classic polyplex analysis techniques, we demonstrate condensation of both immune signals, protection from enzymatic degradation, and tunable physicochemical properties. We show polyplexes reduce TLR signaling, and in primary dendritic cell and T cell co-culture, reduce myelin-driven inflammation. During mouse models of MS, these tolerogenic polyplexes improve the progression, severity, and incidence of disease.